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Background: To present our experience of intensity-modulated radiotherapy (IMRT) with simultaneous modulated
accelerated radiotherapy (SMART) boost technique in patients with nasopharyngeal carcinoma (NPC).
Methods: Sixty eight patients of NPC were treated between April 2006 and December 2011 including 45 males
and 23 females with mean age of 46 (range 15–78). Stage distribution was; stage I 3, stage II 7, stage III 26 and
stage IV 32. Among 45 (66.2%) evaluated patients for presence of Epstein-Barr virus (EBV), 40 (88.8%) were positive
for EBV. Median radiation doses delivered to gross tumor volume (GTV) and positive neck nodes were 66–70 Gy,
63 Gy to clinical target volume (CTV) and 50.4 Gy to clinically negative neck. In addition 56 (82.4%) patients with
bulky tumors (T4/N2+) received neoadjuvant chemotherapy 2–3 cycles (Cisplatin/Docetaxel or Cisplatin/Epirubicin
or Cisplatin/5 Flourouracil). Concurrent chemotherapy with radiation was weekly Cisplatin 40 mg/m2 (40 patients) or
Cisplatin 100 mg/m2 (28 patients).
Results: With a median follow up of 20 months (range 3–43), one patient developed local recurrence, two
experienced regional recurrences and distant failure was seen in 3 patients. Estimated 3 year disease free survival
(DFS) was 94%. Three year DFS for patients with EBV was 100% as compared to 60% without EBV (p = 0.0009).
Three year DFS for patients with undifferentiated histology was 98% as compared to 82% with other histologies
(p = 0.02). Acute grade 3 toxicity was seen as 21 (30.9%) having G-III mucositis and 6 (8.8%) with G-III skin reactions.
Late toxicity was minimal and loss of taste was seen in 3 patients (7.5%) at time of analysis.
Conclusions: IMRT with SMART in combination with chemotherapy is feasible and effective in terms of both the
clinical response and safety profile. EBV, histopathology and nodal involvement were found important prognostic
factors for locoregional recurrence.
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Radiation therapy is considered as the mainstay of treat-
ment in nasopharyngeal carcinoma (NPC) management.
Advances in techniques of radiation delivery, incorpor-
ation of chemotherapy and better imaging tools have
made it possible to achieve local control rate up to 95%.
Radiation Therapy Oncology Group (RTOG) phase II
trial 0225 established the feasibility of translating IMRT
with or without chemotherapy in NPC patients [1].
IMRT is capable of producing highly conformal dose
distributions by manipulating the beam intensity within
different parts of each radiotherapy beam. It provides
improved tumor coverage and spares critical structures
around the tumor (brainstem, parotid glands and optic
structures) when compared with conventional and three
dimensional conformal therapy techniques for NPC
[2,3]. IMRT for NPC decreases late neurologic sequelae
and permanent xerostomia by sparing critical portions
of the brain stem and the parotid glands respectively [4].
The role of chemotherapy either in neoadjuvant setting
before definitive treatment or concurrent with radiation is
a matter of great interest. Concurrent chemotherapy with
radiation therapy has been shown to improve local con-
trol, disease-free survival and overall survival rates for
NPC patients with T2 - T4 diseases, or with neck lymph-
adenopathy. IMRT following neoadjuvant chemotherapy is
a strategy that deserves to be optimized and needs to be
tested in prospective randomized phase III trials in pa-
tients with locoregionally advanced NPC. Neoadjuvant
chemotherapy is an effective way to control subclinical
metastatic foci, especially in lymph node positive patients
of NPC. Moreover, in some patients with large tumors in-
filtrating the brain stem, it is often difficult to deliver the
total required dose to the clinical target volume (CTV)
with preservation of critical tissues. NeoadjuvantFigure 1 High, intermediate and low dose areas in IMRT – SMART plachemotherapy is often able to provide objective responses
in tumor lesions, which offers the possibility to shrink the
CTV and reduce toxicity [5,6].
IMRT with simultaneous modulated accelerated radio-
therapy (SMART) boost technique to enhance biologically
equivalent dose (BED) along with concurrent chemother-
apy, although less studied, has shown excellent local con-
trol rates with minimal toxicity profile, albeit no further
improvement was noted in overall survival [7].
We aimed to evaluate clinical outcomes, efficacy, tox-
icity profile and associated prognostic factors influencing
locoregional and distant control in NPC patients treated
with neoadjuvant chemotherapy followed by IMRT and
SMART concurrent chemoradiation.
Methods
Patients and pretreatment criteria
After institutional review board (IRB) approval, retro-
spective data of sixty- eight consecutive patients with
histologically proven, non-metastatic NPC treated at our
department from April 2006 to December 2011 was
collected. Pretreatment evaluation consisted of complete
history and physical examination, rigid nasendoscopy,
magnetic resonance imaging (MRI), computed tomog-
raphy (CT) imaging of head and neck, CT chest, complete
blood count, liver function tests, renal profile, dental and
audiological assessment prior to the treatment. After May
2008, all the patients were tested for Epstein-Barr virus
(EBV) on histological specimens. Positron emission tom-
ography (PET) imaging, CT abdomen and bone scan were
optional and were performed when clinically indicated.
Patients who had evidence of distant metastasis were not
eligible for this treatment protocol. All patients were
treated after taking informed consent. AJCC 2002 cancer
staging classification was used to stage tumors.n for nasopharyngeal carcinoma.
Table 1 Patients’ characteristics
Variables Number (%)



























Abbreviations: T tumor, N nodes, AJCC American Joint Commission for Cancer,
EBV Epstein-Barr Virus.
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CT simulation was done for all patients in supine position
with thermoplastic masks (S-frame) for immobilization.
Images were acquired with and without contrast using
3mm slices for planning purpose. Pre-chemotherapy MRI
and CT imaging were fused with CT simulation data using
co-registration software where deemed appropriate to
delineate the tumor. The gross tumor volume (GTV) in-
cluded all primary and nodal disease seen on MRI and/
or CT scan. CTV denoted the subclinical regions at risk
for involvement. The high-risk clinical tumor volume
(CTV-1) included GTV plus 5–10 mm margin. CTV-2
as designed for potentially involved regions included the
nasopharyngeal cavity (limited only to the posterior part
of nasal cavity), maxillary sinus (limited to 5-mm an-
terior to the posterior nasal aperture and maxillary
mucosa), pterygopalatine fossa, posterior ethmoid sinus,
parapharyngeal space, skull base, anterior third of clivus
and cervical vertebra, inferior sphenoid sinus and cav-
ernous sinus, and included the retropharyngeal lymph
nodal regions from the base of skull to cranial edge of
the second cervical vertebra. The CTV of the neck
nodal regions included level II, III, IV, V, which was
outlined according to the recommendation by the
RTOG/EORTC CTV delineation protocol for head and
neck malignancies. The planning target volume (PTV) was
created based on each volume with an additional 3-mm
margin, allowing for setup variability. Critical normal
structures including the brainstem, spinal cord, parotid
glands, optic nerves, chiasm, lens, eyeballs, larynx,
esophagus, temporomandibular joints, mandible and
cochlea were contoured and set as organs at risk
(OARs) during optimization. RT was delivered by using
a simultaneous-integrated IMRT boost technique. The
radiation dose delivered was 66-70 Gy in 33–35 frac-
tions (2 Gy per day) to gross tumor (prechemotherapy
volume), 63 Gy in 35 fractions (1.8 Gy per day) to high
risk volume and 50.4 Gy in 28 fractions (1.8 Gy per day)
to low risk volume (Figure 1).
Chemotherapy
Fifty six patients (82.4%) with bulky tumors (T4 or N+)
received neoadjuvant chemotherapy 2–4 cycles. Regimen
used were as; (a) Cisplatin and Docetaxel in 30 patients,
(b) Cisplatin and Epirubicin in 16 patients and (c)
Cisplatin and 5-Flourouracil in 10 patients. Sixty four
patients (91.2%) received concurrent chemoradiation.
Chemotherapy used was either weekly Cisplatin 40 mg/m2
(40 patients) or 3 weekly Cisplatin 100 mg/m2 (24 patients).
Follow-up
All patients were evaluated weekly during radiation ther-
apy. First follow up was at 6 weeks after the completion of
their treatment, then every 2–3 months in the first 2 years,every 6 months from year 2 through year 5, and annually
thereafter. Each follow-up included a complete history,
physical examination and rigid nasendoscopy. CT scan of
the head and neck was performed at 2–3 months post
treatment and afterwards as needed. Acute toxicity profile
during treatment and first three months was assessed by
Common Toxicity Criteria CTC version 3.0 and late toxic-
ities were scored according to the RTOG radiation mor-
bidity scoring criteria at each follow-up.Statistical analyses
The actuarial local/regional control, response rates and
disease-free survival were calculated by life test method.
The duration of time to locoregional failure and distant
metastasis was measured from the date of the completion
of radiation therapy until documented treatment failure.
The duration of DFS was calculated from diagnosis until
Figure 2 Correlation of Epstein Barr virus with 3 year disease free survival (Blue line shows patients with EBV, Red line indicates those
without EBV).
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recurrence. Log-rank test and chi-square were used to
detect the significant difference in survivals between
different prognostic groups. Multivariate analysis using
the Cox proportional hazard model was performed for
the aforementioned endpoints to define independent
predictors among various potential prognostic factors.
Results
Patients’ characteristics are shown in Table 1. Majority of
the patients had locally advanced NPC; stage IV (51.4%)Figure 3 3 year DFS in patients with or without nodal involvement (B
shows patients having N+ disease).and stage III (35%) and majority of cohort had undiffer-
entiated histopathology. Median follow up was of 20
months (range 3–43).
Locoregional, distant control and overall survival rates
Local recurrence occurred in one patient. Regional re-
currence occurred in two patients and distant metastasis
in 3 patients. Sixty two patients (91%) achieved complete
response while 6 patients had partial response (9%). 3 year
DFS for patients with EBV was 100% as compared to 60%
without EBV (p = 0.0009) (Figure 2). Remission andlue line indicates patients with N0 disease, whereas red line
Figure 4 Correlation of histopathology with 3 year DFS (Blue line shows undifferentiated histology, red line indicates all other
histologies).
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0%; 47(96%) vs. 2(4%) with N1/N2 and 5 (71.4%) vs. 2
(28.6%) with N3 (p = 0.02) (Figure 3). 3 year DFS for
patients with undifferentiated histology was 98% as com-
pared to 82% with other histologies (p = 0.02) (Figure 4).
Estimated 3 year disease free survival (DFS) was 94%
(Figure 5).
Univariate and multivariate analysis showed three
prognostic factors significantly affected the locoregional
control; (a) T stage, (b) N stage and (c) presence of EBV
with p values 0.0001, 0.001, 0.002 respectively (Table 2).Figure 5 3 Year disease free survival as determined by Kaplan-Meir eAcute and late toxicity
Regarding acute toxicity, grade 3 mucositis occurred in
21 patients (30.9%) while 16 patients (23%) and 30
patients (44%) developed grade 1 and grade 2 mucositis.
Six patients (8.8%) experienced grade 3 skin reactions
whereas 35 patients (51%) had grade 1 and 25 patients
(37%) had grade 2 skin reactions. Acute loss of taste
took place in 19 patients (27.9%). Late toxicity was min-
imal with chronic xerostomia (Grade 2) seen in 3 patients
(7.5%) among 40 available patients at time of analysis
while 10 patients (25%) had Grade 1 Xerostomia. Salivarystimates.
Table 2 Multivariate analysis of prognostic factors
affecting locoregional control in patients with
nasopharyngeal carcinoma
Prognostic factor Hazard ratio 95% CI p-value
Age groups (years)
Below 40 1.1 0.8-1.4 0.07
Above 40 1.0 - 0.9
Gender
Male 1.0 - 0.9
Female 1.0 -
T stage
T1 and T2 1.8 1.3-2.2 0.04
T3 and T4 4.2 3.8-4.6 0.0001
N stage
N0 and N1 0.8 0.6-1.0 0.04
N2 and N3 3.8 3.4-4.2 0.001
EBV status
Positive 0.7 0.8-1.4 0.002
Negative 1.8 1.3-2.2 0.04
Abbreviations: T tumor, N node, EBV Epstein-Barr virus.
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them 25 (37%) had Grade 1 changes while 7 (10%) had
Grade 2 inflammation. After CCRT, Grade 1 impaired
hearing occurred in 15 patients (22%) while 3 patients
(4.5%) experienced Grade 2 hearing loss.
Discussion
NPC ranks fourth in the list of first five tumors in Saudi
Arabia among young males 30–44 years according to
Saudi cancer registry 2005 and about 80% of tumors are
T3, T4 or node positive [7]. For such locally advanced
NPC patients, chemoradiation incorporating chemother-
apy along with IMRT is practical and feasible in terms of
clinical efficacy and toxicity. SMART has been employed
to further enhance BED in this setting. Long-term re-
sults show excellent local tumor control with less late
toxicity but no further improvement in overall survival
[8]. IMRT with simultaneous integrated boost (SIB)
technique for locoregionally advanced NPC was effective
regarding locoregional control and development of
xerostomia, even after neoadjuvant chemotherapy [9,10].
A review was conducted by Tham et al. on case records
of 195 patients with histologically proven, nonmetastatic
NPC treated with IMRT between 2002 and 2005. They
concluded that local failure or persistent disease, espe-
cially in patients with bulky T4 tumors were issues that
must be addressed in future trials [11]. In another study by
Han L et al., they concluded that IMRT provided favorable
locoregional control and survival rates in locally advanced
disease. The acute and late toxicities were acceptable and
nodal classification was the main factor of prognosis [8].Ng WT et al. reported 2-year local progression-free, re-
gional progression-free, distant metastasis-free and overall
survival rates as 95%, 96%, 90%, and 92%, respectively thus
conferring that IMRT provides excellent locoregional
control for NPC [12].
This is the first study to evaluate the role of IMRT
after induction chemotherapy as well as concomitant
with chemotherapy in Saudi Arabia. Overall response
was seen in 90% although majority of the patients
belonged to stage III & IV (86%) which concludes that
IMRT together with chemotherapy, induction and or con-
comitant is an effective strategy in management of NPC.
One useful biomarker (particularly for nonkeratinizing
carcinoma) is the plasma level of EBV deoxyribonucleic
acid, and its role as a tool for prognostication and moni-
toring is rapidly evolving [13]. Our study also proved
EBV as a sound prognostic factor.
Historical local control (LC) rates for patients under-
going conventional RT range from 64% to 95% for T1-2
tumors but decreases to 44% to 68% in T3-4 lesions.
Most contemporary series have reported encouraging re-
sults with CCRT, with locoregional control exceeding
90%; the key problem is distant failure. Although signifi-
cant reduction of some toxicities (e.g., xerostomia) and
better quality of life is now achievable especially for early
stages, the risk of major late toxicities remains substan-
tial. Lee et al. showed grade 2 xerostomia in 64% of
patients, grade 1 in 28% and grade 0 in 8% at 3 months
after IMRT. At 24 months after IMRT, only 1 out of 41
evaluable patients had grade 2, 32% had grade 1 and
66% had grade 0 xerostomia showing that it decreases
markedly over time [14]. IMRT enables coverage of ir-
regularly shaped tumor while limiting the dose to critical
structures and avoids under dosing the portions of
tumors [15].
Neoadjuvant chemotherapy inclusion and radiotherapy
optimization methods are two potential areas of interest
that need further elaboration in multicenter randomized
prospective trials. Phase II studies were done to evaluate
the efficacy and safety of neoadjuvant chemotherapy with
a regimen of Docetaxel, Cisplatin, and 5 fluorouracil
(TPF) followed by radiotherapy and concurrent Cisplatin
in patients with stage III and IV (A-B) NPC indicating
that it was well tolerated with a manageable toxicity
profile [16].
The effect of radiotherapy optimization technique
was demonstrated in a recent Italian phase II trial by
Palazzi et al. which enrolled 87 patients with NPC who
were treated with either conventional (two- or three-
dimensional) radiotherapy or with IMRT. Of these
patients, 26% received only concurrent cisplatin and the
other 74% received both induction and concurrent CT.
Three-year DFS and OS were 82% and 90%, respectively.
Outcome of NPC further improved in the study period
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fect of RT technique optimization [16].
Main limitations of our study are related to its retro-
spective nature, inability to test all the patients for EBV
and non-uniformity of chemotherapeutic agent's selection.
Conclusions
In conclusion, neoadjuvant CT followed by IMRT and
concurrent CT in NPC patients is feasible and effective in
terms of toxicity and response. EBV, histopathology and
nodal involvement were found to be important prognostic
factors for locoregional recurrence.
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